Subcutaneous Epcoritamab Shows Durable Responses in Elderly B-Cell Lymphoma
Phase 2 data support epcoritamab monotherapy as a promising chemotherapy-free option for older patients with newly diagnosed LBCL.
Related Articles
Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer
Spatial and molecular profiling of 117 tumors before and after chemotherapy reveals a dynamic tumor ecosystem in ovarian cancer. Launonen et al. identify Myelonets as drivers…
‘The Opportunities Are Endless’: CU Cancer Center Leader Signs Key International Agreement
A CU Cancer Center global oncology leader has returned from Mexico, where he signed the first of many agreements with cancer centers in Latin America.
Discovery of Gene Linked to High-Altitude Adaptation May Transform Blood Cancer Care
Huntsman Cancer Institute researchers have identified a gene variant found in a high-altitude Andean population that may predict severity of diseases and responses to treatments…
Risk-reducing surgeries extend survival among young BRCA carriers with breast cancer history
SAN ANTONIO — Risk-reducing surgery appeared linked with improved outcomes among BRCA mutation carriers diagnosed with early breast cancer, according to study results presented at…
Registration
Register for the AACR Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois.
Risk-Reducing Surgery Improves Survival Outcomes in Younger BRCA+ Breast Cancer
Risk-reducing surgery improved survival outcomes in younger patients with breast cancer and a germline BRCA mutation.
T-DXd Improves PFS Irrespective of Time to Progression, Type of Endocrine Resistance in HER2-Low/-Ultralow Metastatic Breast Cancer
T-DXd improved PFS vs treatment of physician’s choice in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer.
Breast cancer researcher receives lecture award at SABCS
Laura J. van ’t Veer, PhD, will receive the William L. McGuire Memorial Lecture Award at this year’s San Antonio Breast Cancer Symposium, scheduled for…
Brian Druker steps down as CEO of OHSU Knight Cancer Center – The Cancer Letter
On Dec. 3, the faculty and staff members at the OHSU Knight Cancer Institute received an email from Brian J. Druker, the institution’s star scientist,…
High5 Oncology TV: SABCS 2024
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend. Jetzt gleich den Fragebogen ausfüllen! Durch…
